 |
市场调查报告书
商品编码
1122335
ANCA 相关血管炎药物市场：按类型、药物类型、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030ANCA Vasculitis Drug Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
抗中性粒细胞胞质自身抗体 (ANCA) 相关性血管炎 (AAV) 是一组以小血管炎症和损伤为特征的自身免疫性疾病。一种称为 ANCA 的自身反应性抗体负责这种炎症，因为它与中性粒细胞结合併过度激活。这种免疫系统故障是由遗传和环境因素引起的。根据受影响的器官或身体部位，ANCA 血管炎会引起各种症状。例如，如果皮肤中的血管受损，可能会出现皮疹。此外，当肾臟的血管受损时，血液和蛋白质会渗入尿液，从而对肾臟造成损害。 ANCA 血管炎主要分为三种类型：显微镜下多血管炎（MPA）、肉芽肿性多血管炎（GPA）和嗜酸性肉芽肿性多血管炎（EGPA）。目前还没有治愈这种疾病的方法，并给予治疗来控制病情。患者通常分两个阶段接受治疗：诱导症状缓解的治疗（诱导治疗）和尽可能长时间维持缓解的治疗（维持治疗）。
市场动态
市场上的主要参与者专注于开展研发活动并在各种医学会议上展示他们的研究成果，预计这将在预测期内推动市场增长。例如，2022 年 5 月，生物製药公司 ChemoCentryx, Inc. 宣布了关键的 3 期 ADVOCATE 试验结果，并宣布即将在三个主要医学会议上发表演讲，重点是调查糖皮质激素在 ANCA 相关血管炎中的使用负担。会议：ATS 2022（美国胸科学会）2022 年 5 月 15 日至 17 日；旧金山，ISPOR 2022（国际药学和结果学会）2022 年 5 月 15 日至 18 日；华盛顿，第 59 届 ERA 会议（欧洲会议）5 月 19 日至 22 日， 2022，法国巴黎/虚拟
本研究的主要特点
- 本报告对全球 ANCA 血管炎药物市场进行了深入分析，提供了以 2021 年为基准年的预测期间（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。
- 解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
- 根据公司亮点、产品组合、关键亮点、财务业绩和战略等参数，介绍了全球 ANCA 血管炎治疗市场的主要参与者的概况。
- 本研究涵盖的主要公司包括 ChemoCentryx, Inc.、Vifor Pharma、GlaxoSmithKline plc、Amgen、Genentech, Inc.、Pfizer Inc.、Biogen、InflaRx GmbH 和 AstraZeneca
- 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
- 全球 ANCA 血管炎药物市场报告迎合了该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
- 利益相关者可以通过用于分析全球 ANCA 血管炎药物市场的各种战略矩阵来促进决策制定。
内容
第 1 章目的和先决条件
- 调查目的
- 先决条件
- 缩写说明
第二章市场展望
- 举报内容
- 市场定义和范围
- 执行摘要
- 市场快照：按类型
- 按药物类型划分的市场概况
- 市场快照：按分销渠道
- 市场概况，按国家/地区分类
- 连贯的机会图 (COM)
第 3 章市场动态、法规和趋势分析
- 市场动态
- 驱动程序
- 限制因素
- 市场机会
- 影响分析
- 市场趋势
- 主要发展状况
- 监管场景
- PEST 分析
- 流行病学
- 产品发布/批准
第 4 章 ANCA 相关血管炎治疗药物的全球市场 - 冠状病毒 (COVID-19) 大流行的影响
- 经济影响
- COVID-19 流行病学调查
- 供需分析
第 5 章 2017-2030 年按类型分列的 ANCA 相关血管炎药物全球市场
- 肉芽肿性多血管炎 (GPA)
- 显微镜下多血管炎 (MPA)
- 肉芽肿伴嗜酸性多血管炎 (EGPA)
- 肾局限性血管炎
第 6 章全球 ANCA 相关血管炎药物市场，按药物类型，2017-2030 年
- 糖皮质激素
- 环磷□胺
- 利妥昔单抗
- 甲氨蝶呤
- 吗替麦考酚酯
- 硫唑嘌呤
- 美泊利单抗
- 阿巴科麵包
- 其他
第 7 章全球 ANCA 相关血管炎治疗市场，按分销渠道，2017-2030 年
- 医院药房
- 零售药房
- 在线药店
第 8 章全球 ANCA 相关血管炎药物市场：2017-2030 年按地区分列
- 北美
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地区
- 欧洲
- 英国
- 德国
- 意大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 东盟
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东
- 海合会
- 以色列
- 其他中东
- 非洲
- 北非
- 中非
- 南非
第 9 章竞争格局
- ChemoCentryx, Inc.
- Vifor Pharma
- GlaxoSmithKline plc
- Amgen
- Genentech, Inc.
- Pfizer Inc.
- Biogen
- InflaRx GmbH
- AstraZeneca
第 10 章
- 调查方法
- 关于出版商
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).
Market Dynamics
Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual
Key features of the study:
- This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ANCA vasculitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market
Detailed Segmentation:
- Global ANCA Vasculitis Drug Market, By Type:
- Granulomatosis with Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Renal-limited Vasculitis
- Global ANCA Vasculitis Drug Market, By Drug Type:
- Glucocorticoids
- Cyclophosphamide
- Rituximab
- Methotrexate
- Mycophenolate mofetil
- Azathioprine
- Mepolizumab
- Avacopan
- Others
- Global ANCA Vasculitis Drug Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global ANCA Vasculitis Drug Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- ChemoCentryx, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Vifor Pharma
- GlaxoSmithKline plc
- Amgen
- Genentech, Inc.
- Pfizer Inc.
- Biogen
- InflaRx GmbH
- AstraZeneca
- ChemoCentryx, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Country
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Product Launch/Approvals
4. Global ANCA Vasculitis Drug Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Demand and Supply Analysis
5. Global ANCA Vasculitis Drug Market, By Type, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Granulomatosis with Polyangiitis (GPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Microscopic Polyangiitis (MPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Renal-limited Vasculitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global ANCA Vasculitis Drug Market, By Drug Type, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Glucocorticoids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Cyclophosphamide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Rituximab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Methotrexate
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Mycophenolate mofetil
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Azathioprine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Mepolizumab
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Avacopan
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global ANCA Vasculitis Drug Market, By Distribution Channel, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global ANCA Vasculitis Drug Market, By Region, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- ChemoCentryx, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Vifor Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- InflaRx GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
